Arrowhead Pharmaceuticals have announced participating in several conferences in October, covering cystic fibrosis, Oligonucleotide-Based Therapeutics, and genetic medicines topics.
PASADENA, Calif.–(BUSINESS WIRE)–$arwr–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
2019 Cantor Global Healthcare Conference – New York, October 2-4, 2019
October 4, 10:05 a.m. EDT – Vince Anzalone, CFA, Arrowhead’s vice president of investor relations, will participate in a fireside chat presentation with Elemer Piros, Ph.D., Cantor Fitzgerald biotechnology equity research analyst
Chardan 3rd Annual Genetic Medicines Conference – New York, October 7-8, 2019
October 7, 1:30 p.m. EDT – Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will participate in a fireside chat presentation with Keay Nakae, CFA, Chardan senior research analyst
Arrowhead Pharmaceuticals Analyst R&D Day – New York, October 18, 2019
October 18, 8:30-11:30 a.m. EDT – Arrowhead and outside experts will provide updates on the company’s emerging pipeline of RNAi therapeutics and review advancements being made to the proprietary Targeted RNAi Molecule (TRiMTM) platform
DIA/FDA Oligonucleotide-Based Therapeutics Conference – North Bethesda, MD, October 28-30, 2019
October 28, 2:30 p.m. EDT – James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “The emerging safety and activity of siRNA drugs using the TRIMTM platform”
North American Cystic Fibrosis Conference – Nashville, October 31-November 2, 2019
October 31, 11:15 a.m. CDT – Erik Bush, Ph.D., Arrowhead’s vice president of extra-hepatic targeting, will deliver a poster presentation titled, “Therapeutic Inhibition of ENaC With a Lung-Targeted RNAi Molecule Delivery Platform Preserves Normal Mucus Clearance in a Mucostatic Sheep Model of Cystic Fibrosis”